Gilder Gagnon Howe & CO LLC 89bio, Inc. Transaction History

Gilder Gagnon Howe & CO LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$15.06 - $19.41 $3,674 - $4,736	244 Added 0.3%	81,207 $1.25 Million
Q2 2023 Aug 14, 2023	BUY	$14.15 - $22.03 $70,184 - $109,268	4,960 Added 6.53%	80,963 $1.53 Million
Q1 2023 May 15, 2023	BUY	$10.48 - $16.94 $273,800 - $442,574	26,126 Added 52.38%	76,003 $1.16 Million
Q4 2022 Feb 14, 2023	BUY	$5.52 - $12.73 $275,321 - $634,934	49,877 New	49,877 $634,000
Q2 2021 Aug 16, 2021	SELL	$17.42 - $28.0 $538,556 - $865,648	-30,916 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$20.22 - $26.73 $19,876 - $26,275	-983 Reduced 3.08%	30,916 $732,000
Q4 2020 Feb 16, 2021	SELL	$23.16 - $28.08 $8,082 - $9,799	-349 Reduced 1.08%	31,899 $777,000
Q3 2020 Nov 16, 2020	BUY	$24.34 - $38.82 $784,916 - $1.25 Million	32,248 New	32,248 $827,000

158

108M

73.6K

1.19M

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $387M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of Gilder Gagnon Howe & CO LLC, based on Form 13F filings with the SEC.

Stay updated on Gilder Gagnon Howe & CO LLC with notifications on news.